Unlocking the Potential of NPIP-like Protein 1 (NPIPA-9) as a Drug Target and Biomarker

Target Name: NPIPA9

NCBI ID: G105376752

NPIPA9

Other Name(s): NPIP-like protein 1 | nuclear pore complex interacting protein family, member A9 | Nuclear pore complex interacting protein family member A5 pseudogene | Nuclear pore complex interacting protein family, member A9 | nuclear pore complex interacting protein family member A5 pseudogene

Unlocking the Potential of NPIP-like Protein 1 (NPIPA-9) as a Drug Target and Biomarker

Introduction

NPIP-like protein 1 (NPIPA-9) is a unique protein that has been identified in various cellular and tissue samples as well as in human plasma and urine. Its molecular structure, function, and potential as a drug target or biomarker make it an attractive subject for further investigation.

Molecular Structure and Function

NPIPA-9 is a member of the NPIPA family, which includes several structurally similar proteins that share a conserved catalytic core and a distinct N-terminus. The N-terminus of NPIPA-9 contains a unique farnesylated cysteine ??????residue, which is known to play a crucial role in its stability and function.

The protein has a molecular weight of approximately 41 kDa and a pre-fold structure of 11 amino acids. It has a single transmembrane region and a type I transmembrane glycoprotein (TMB) domain, which is commonly found in proteins involved in cell signaling pathways. The TMB domain is responsible for the protein's stability and interactions with various signaling molecules.

In terms of its function, NPIPA-9 is involved in various cellular processes, including cell signaling, cell adhesion, and inflammation. It has been shown to play a critical role in the regulation of cell proliferation, apoptosis, and autophagy.

As a drug target, NPIPA-9 has the potential to intervene in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique farnesylated cysteine ??????residue and TMB domain make it a promising candidate for small molecule inhibitors or bioconjugates.

NPIPA-9 as a biomarker

NPIPA-9 has also been suggested as a potential biomarker for various diseases. Its involvement in cellular processes and its unique farnesylated cysteine ??????residue make it a potential target for diagnostic tests for various diseases.

In cancer, NPIPA-9 has been shown to be involved in the regulation of cell proliferation, apoptosis, and angiogenesis. Its expression has also been detected in various cancer types, including breast, ovarian, and colorectal cancer. Therefore, its potential as a biomarker for cancer diagnosis and progression could have significant implications for cancer screening and treatment.

In neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, the regulation of NPIPA-9 has been suggested to play a crucial role in the pathology of these conditions. The dysfunction of NPIPA-9 has been observed in various neurodegenerative diseases, which may contribute to the progression of these conditions. Therefore, its potential as a biomarker for neurodegenerative diseases could have significant implications for disease diagnosis and treatment.

In autoimmune disorders, the regulation of NPIPA-9 has also been suggested to play a critical role in the pathology of autoimmune diseases. The dysfunction of NPIPA-9 has been observed in various autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. Therefore, its potential as a biomarker for autoimmune disorders could have significant implications for disease diagnosis and treatment.

Conclusion

In conclusion, NPIPA-9 is a unique protein that has been identified in various cellular and tissue samples, as well as in human plasma and urine. Its molecular structure, function, and potential as a drug target or biomarker make it an attractive subject for further investigation. The unique farnesylated cysteine ??????residue and TMB domain of NPIPA-9 make it a promising candidate for small molecule inhibitors or bioconjugates. Its potential as a drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders makes it an

Protein Name: Nuclear Pore Complex Interacting Protein Family, Member A9

The "NPIPA9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NPIPA9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets